A Phase 1 interventional study of Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL) and Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL) in Healthy Adult Subjects, sponsored by Connect Biopharm LLC. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-31.
Sponsored by Connect Biopharm LLC · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, randomized, open-label, single-dose, parallel-designed PK similarity study.
A total of 324 healthy subjects are planned to be enrolled and randomized into 3 groups at a ratio of 1:1:1, with 108 subjects in each group. They will receive 2 doses of the test drug T1 (CBP-201 injection (pre-filled syringe, 150 mg/1 mL)), 1 dose of the test drug T2 (CBP-201 injection (pre-filled syringe, 300 mg/2 mL)), and 2 doses of the reference drug R (CBP-201 injection (vial, 150 mg/1 mL)), respectively.
The study consists of a screening period (Day-28 to Day-2), a baseline period (Day-1), an administration and observation period (Day1 to Day6), and a follow-up period (Day7 to Day57).
Connect Biopharm LLC is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with active tuberculosis, latent tuberculosis, or nontuberculous mycobacterial infection at screening;
Notes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Strength: pre-filled syringe, 150 mg/1 mL
Biological: Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)
Strength: pre-filled syringe, 300 mg/2 mL
Biological: Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL)
Strength: vial, 150 mg/1 mL
Biological: Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL)
Drug page: CBP-201
subcutaneous injection of 2 doses on Day 1
Drug page: CBP-201
subcutaneous injection of 1 dose on Day 1
Drug page: CBP-201
subcutaneous injection of 2 doses on Day 1
Cmax: Maximum concentration
Pharmacokinetics similarity evaluation for test drug T1, test drug T2 and reference drug R
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
AUC0-t: Area under the plasma concentration-time curve from the start of administration to the last measurable concentration time point T
Pharmacokinetics similarity evaluation for test drug T1, test drug T2 and reference drug R
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
AUC0-inf: Area under the plasma concentration-time curve from the start of administration to infinity
Pharmacokinetics similarity evaluation for test drug T1, test drug T2 and reference drug R
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
Maximum concentration (Cmax)
Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
Area under the plasma concentration-time curve from the start of administration to the last measurable concentration time point T (AUC0-t)
Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
Area under the plasma concentration-time curve from the start of administration to infinity (AUC0-inf)
Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
Time to peak (Tmax)
Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
Elimination half-life (t1/2)
Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
Apparent clearance (CL/F)
Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
Apparent volume of distribution (Vz/F)
Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
Terminal elimination phase rate constant (λz)
Calculated by non-compartmental analysis (NCA) using WinNonLin V8.3.1 (or higher version)
Time frame: Pre-dose and 6hour, 24hour, 48hour, 72hour, 96hour, 120hour, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57 post-dose
Adverse events (AEs)
All adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA) (the latest version).
Time frame: Up to 57 days post dosing
Injection site reactions
The injection site will be examined and the results will be judged by the investigator.
Time frame: Day1, Day2, Day3, Day4, Day6, Day8, Day15, Day22, Day29, Day57
Blood Pressure (systolic and diastolic blood pressures)
The results as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57
Pulse
The results as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57
Body Temperature (ear temperature)
The results as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57
Respiratory Rate
The results as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day1, Day2, Day3, Day4, Day6, Day8, Day10, Day11, Day12, Day15, Day18, Day22, Day29, Day36, Day43, Day57
Physical examination
Physical examination items include: skin (including observation of the planned injection site (abdomen) and surrounding skin during the screening period and at baseline), lymph nodes, head, eyes, neck, chest, abdomen, spine/extremities, and nervous system. The results of physical examination will be evaluated by investigator's observation.
Time frame: pre-dose, Day6, Day15, Day29, Day57
12-lead electrocardiogram (ECG)
ECG variables include ventricular heart rate, PR interval, QRS interval, QT interval, and QTcF interval.
Time frame: pre-dose, Day1, Day2, Day4, Day6, Day10, Day15, Day22, Day29, Day36, Day43, Day57
Clinical laboratory test: Hematology - Hemoglobin (Hgb)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - Hematocrit (Hct)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - red blood cell count (RBC)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - platelet count
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - white blood cell count (WBC)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - lymphocyte count
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - lymphocyte percentage
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - neutrophil count
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - neutrophil percentage
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - monocyte count
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - monocyte percentage
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - eosinophil count
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - eosinophil percentage
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - basophil count
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - basophil percentage
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - mean corpuscular hemoglobin (MCH)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Hematology - mean corpuscular volume (MCV)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Urinalysis
Urine protein, cast, urine red blood cells, urine white blood cells, urine pH, urine ketone body, glucose urine, urine bilirubin, and urine occult blood
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - Glucose (Glu)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - alanine aminotransferase (ALT)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - aspartate aminotransferase (AST)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - alkaline phosphatase (ALP)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - lactate dehydrogenase (LDH)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - gamma-glutamyltransferase (γ-GGT)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - serum total protein (TP)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - albumin (ALB)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - total bilirubin (TBIL)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - direct bilirubin (DBIL)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - blood urea nitrogen (BUN)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - creatinine (Crea)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - sodium (Na)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - potassium (K)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - chlorine (Cl)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - calcium (Ca)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - phosphorus (P)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - triglycerides (TG)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - total cholesterol (TC)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - high-density lipoprotein cholesterol (HDL-C)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - low-density lipoprotein cholesterol (LDL-C)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - uric acid (UA)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Biochemistry - creatine kinase (CK)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Coagulation - International normalized ratio (INR)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Coagulation - prothrombin time (PT)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Coagulation - activated partial thromboplastin time (APTT)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Coagulation - fibrinogen (FIB)
The results of clinical laboratory tests, as well as their changes from baseline will be statistically summarized by dose group and visit.
Time frame: pre-dose, Day6, Day15, Day29, Day43, Day57
Clinical laboratory test: Pregnancy test
Blood pregnancy test (for females only)
Time frame: pre-dose, Day15, Day29, Day43, Day57
Clinical laboratory test: Infectious serology
Hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, Treponema pallidum antibody, and human immunodeficiency virus antibody
Time frame: pre-dose
Clinical laboratory test: Blood alcohol test
Blood alcohol test
Time frame: pre-dose
Clinical laboratory test: Urine drug abuse screening
Morphine, methamphetamine, ketamine, methylenedioxy methylamphetamine, marijuana, and cocaine
Time frame: pre-dose
T-Spot
If necessary, T-spot screening can be performed for priorly infected or suspected patients
Time frame: pre-dose
Immunogenicity: The positive rate and titer of anti-drug antibody (ADA), and the positive rate of neutralizing antibody (Nab, in case of ADA positive results)
Immunogenicity will be analyzed based on IMS. The number and percentage of subjects positive for CBP-201 ADA and Nab will be summarized by dose group.
Time frame: pre-dose, Day11, Day29, Day43, Day57
Ran from Jul 2023 to primary completion in Oct 2023, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CBP-201
Connect Biopharm LLC